nadofaragene firadenovec-vncg
nadofaragene firadenovec-vncg is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including ADSTILADRIN. Available dosage form: suspension.
Drug Details
- Generic Name
- nadofaragene firadenovec-vncg
- Brand Names
- ADSTILADRIN
- Application Number
- BLA125700
- Sponsor
- Ferring Pharmaceuticals Inc.
- NDC Codes
- 1
- Dosage Forms
- SUSPENSION
- Routes
- INTRAVESICAL
- Active Ingredients
- NADOFARAGENE FIRADENOVEC
Indications and Usage
1 INDICATIONS AND USAGE ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )